Continued decline. After the transaction ended on the 5th, it was announced that the analysis results of the phase 2 stemtra test of the main development product SB623 were published in Neurology. It is said that analysis results evaluating the efficacy and safety up to 48 weeks (final) of the Phase 2 multi-center joint pseudosurgery control randomized double blind comparison test (STEMTRA test) aimed at examining the efficacy and safety of the main development product SB623 were published for patients with chronic motor dysfunction due to traumatic brain injury performed from 2016 to 2019.
サンバイオ---続落、主要開発品SB623のフェーズ2試験の良好な解析結果がNeurology誌に掲載
SBI Biotech - Continued decline, favorable analysis results of Phase 2 trial of major development product SB623 published in Neurology journal
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.